Background {#Sec1}
==========

Serotonin (5-HT~3~) receptor antagonists are a class of antiemetics recommended for patients undergoing surgery who are at risk for nausea and vomiting \[[@CR1], [@CR2]\]. Serotonin (5-HT~3~) receptor antagonists reduce nausea and vomiting by inhibiting vagal nerves in the central nervous system and intestinal mucosa \[[@CR3]\]. However, some evidence suggests that 5-HT~3~ receptor antagonists can increase the risk of cardiac harm in children undergoing chemotherapy \[[@CR4], [@CR5]\]. Adverse events associated with these medications include a decrease in heart rate and prolongation of the QT interval. We were commissioned by Health Canada, a department of the federal government, to determine the comparative safety of 5-HT~3~ receptor antagonists for patients of all ages undergoing surgery due to safety concerns regarding the 5-HT~3~ receptor antagonists.

Methods {#Sec2}
=======

We used an integrated knowledge translation approach \[[@CR6]\], entailing collaboration between researchers and research users throughout the conduct of this study. The research users involved in this study who posed the original study question were from Health Canada.

Protocol {#Sec3}
--------

A protocol was developed and revised using feedback from the research team and the research users. We registered our protocol with PROSPERO (CRD42013003564) and published it in an open-access journal \[[@CR7]\]. Our methods are described briefly here; additional details can be found in the protocol publication. We originally intended to evaluate both safety and efficacy outcomes for patients undergoing surgery or chemotherapy; however, due to the enormous number of studies that met the inclusion criteria, we made slight changes to our protocol and subdivided the analyses. The current paper focuses on the safety of 5-HT~3~ antagonists in patients undergoing surgery. Subsequent papers will examine the efficacy of 5-HT~3~ antagonists for patients undergoing surgery \[[@CR8]\], and the efficacy and safety of 5-HT~3~ antagonists for patients undergoing chemotherapy.

Eligibility criteria {#Sec4}
--------------------

We included experimental (randomized clinical trials (RCTs), quasi-RCTs, non-RCTs), quasi-experimental (interrupted time series, controlled before--after studies), and observational (cohort) studies involving patients of any age undergoing any type of surgery who were given a 5-HT~3~ receptor antagonist for nausea and/or vomiting. A list of the agents and relevant comparators that were investigated in the included studies can be found in Additional file [1](#MOESM1){ref-type="media"}: Appendix 1. The primary outcome was the number of patients experiencing arrhythmia, and secondary outcomes were QT prolongation, PR prolongation, delirium, and mortality (overall and sudden cardiac death). Given the large number of included studies we limited the review to those published in English. Studies suspected or identified as fraudulent were excluded \[[@CR9]\].

Information sources {#Sec5}
-------------------

An experienced librarian executed searches of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception until 11 January 2013. Unpublished studies were sought by searching trial protocol registries and conference proceedings.

Study selection and data collection {#Sec6}
-----------------------------------

After a calibration exercise, the literature search results were screened by pairs of reviewers, working independently. The same approach was used to abstract data and appraise the quality of included studies. Conflicts at both the screening and the abstraction steps were resolved through discussion. When data was missing or clarification of published data was needed we contacted the authors.

Appraisal of methodological quality and risk of bias {#Sec7}
----------------------------------------------------

To assess methodological quality and risk of bias of the included studies, we used the Cochrane Effective Practice and Organisation of Care risk of bias tool for experimental and quasi-experimental studies \[[@CR10]\], the Newcastle-Ottawa Scale \[[@CR11]\] for cohort studies, and the McMaster Quality Assessment Scale of Harms (known as the McHarm tool) \[[@CR12]\] for studies reporting harms.

Synthesis of included studies {#Sec8}
-----------------------------

A pooled estimate of effect was derived on the odds ratio (OR) scale using random-effects pairwise meta-analysis for each outcome and comparison, if at least two studies were available. When studies reported zero events in one treatment arm, 0.5 was added to the numerator and 1 was added to the denominator. Studies with zero events in both arms were excluded from the analyses. Between-study heterogeneity for direct-comparison meta-analysis was estimated using the restricted maximum likelihood (REML) \[[@CR13]\] and measured using the *I*^*2*^ statistic \[[@CR14]\]. Each pairwise meta-analysis estimate is presented along with the corresponding 95% confidence interval (CI). These analyses were conducted using the metafor package \[[@CR15]\] in R 3.1.2 \[[@CR16]\].

Before embarking on network meta-analysis (NMA), we evaluated the transitivity assumption by examining the comparability of the distributions of age (children versus adults), timing of administration (all time points versus during surgery), and risk of bias (all versus removing high risk of bias for randomization, allocation concealment, and blinding of outcome assessor) as potential treatment-effect modifiers across comparisons \[[@CR17]\]. For each outcome, we visually inspected the potential effect modifiers by using colored edges in the network according to the level of the effect modifier and the majority of trials included in each comparison \[[@CR18]\]. We evaluated the consistency assumption for the entire network using the design-by-treatment interaction model \[[@CR19]\]. In case we found statistically significant inconsistency, we planned to assess certain paths of the network using the loop-specific method \[[@CR20], [@CR21]\] to identify which piece of evidence was responsible for the inconsistency (i.e., local inconsistency). We also planned to apply network meta-regression to adjust for potential effect modifiers if local inconsistency was identified. NMAs were performed within a frequentist framework, assuming a common within-network estimate for the heterogeneity parameter across all comparisons and estimated with the REML \[[@CR13], [@CR19]\]. We used the surface under the cumulative ranking (SUCRA) curve to rank the safety of the various 5-HT~3~ receptor antagonists \[[@CR22]\].

The treatment nodes were selected with input from clinicians, pharmacists, and statisticians on the team. Due to the complexity of the analysis, we did not account for differences in doses and durations assuming that all impact the treatment effect equally. Specifically, when a study compared different doses of an intervention against another intervention, we included only the recommended dose in the analysis \[[@CR1], [@CR23]--[@CR33]\].

The summary treatment effect generated by each NMA is presented along with its 95 % CI and 95 % predictive interval (PrI). The PrI, representing the interval within which the estimated treatment effect of a future study is expected to lie, captures the uncertainty of the NMA estimate and the magnitude of heterogeneity within the network overall \[[@CR34], [@CR35]\]. To assess the presence of reporting bias (including publication bias and small-study effects), we applied the comparison-adjusted funnel plot for each outcome separately \[[@CR18]\]. We ordered the treatments from oldest to newest and then plotted the difference between each study-specific treatment effect and the corresponding comparison-specific summary effect under the fixed-effect model, against the study-specific standard error. We carried out subgroup analyses for all outcomes according to the timing of administration of 5-HT~3~ receptor antagonist therapy (all time periods versus during surgery) and age (all ages versus children). To establish the robustness of our results, we performed a sensitivity analysis in which we excluded studies with high risk of bias because of incomplete outcome data. Given that our primary analysis was a network meta-analysis restricted to RCTs, we conducted a second sensitivity analysis in which non-randomized studies were added to the network, to observe the contribution of different study designs to the treatment effects. Network meta-analyses were conducted using the mvmeta command in Stata 13.0 \[[@CR36], [@CR37]\].

Results {#Sec9}
=======

Literature search {#Sec10}
-----------------

After screening 7,608 citations, we reviewed 1,014 potentially relevant full-text articles and identified 115 primary publications \[[@CR10], [@CR33], [@CR38]--[@CR150]\] and five companion reports \[[@CR151]--[@CR154]\] (reporting on six studies) providing data on 27,787 patients that met our inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). Overall, 77 studies were excluded because they reported results suspected or confirmed to be fraudulent \[[@CR9]\]. One of the included studies was an unpublished conference abstract \[[@CR84]\].Fig. 1Study flow. Details the flow of information through the different phases of the review; maps out the number of records identified, included and excluded, and the reasons for their exclusion

Study and patient characteristics {#Sec11}
---------------------------------

The majority of the included studies were RCTs (97 %), conducted in Europe (37 %), North America (26 %), or Asia (24 %) and published between 1990 and 2013 (Table [1](#Tab1){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Appendix 2). The duration of follow-up was very short, ranging from ≤6 h to more than a week. The most frequent follow-up time observed was 12 to 24 h (69 %). The setting was not reported in the majority of trials (62 %) (Table [1](#Tab1){ref-type="table"}).Table 1Study characteristicsCharacteristicNumber of studies^a^ (n = 115)Percentage of studies (%)**Year of publication**1990--199476.11995--19993732.22000--20041916.52005--20093631.32010--20131613.9**Geographic region**Europe4236.5North America3026.1Asia2824.3Multi-continent87.0Australasia32.6Africa21.7Not reported10.9South America10.9**Study design**Randomized clinical trial11297.4Non-randomized clinical trial21.7Controlled before--after study10.9**Study conduct period**1990--199910.92000--20091513.02010--201310.9Not reported9885.2**Duration of follow-up** ^**b**^0 to ≤697.8\>6 to ≤1221.7\>12 to ≤247968.7\>24 to ≤481714.8\>48 to ≤7221.7\>72 to ≤1 week32.6Not reported32.6**Interventions examined: frequency** ^**c**^*Serotonin antagonists:* Reported as administered alone (administered with dexamethasone)Ondansetron79 (7)68.70 (6.1)Granisetron14 (4)12.2 (3.5)Tropisetron15 (0)13.0 (0.0)Dolasetron15 (1)13.0 (0.9)Palonosetron4 (0)3.5 (0.0)Ramosetron3 (1)2.6 (0.9)*Comparator antiemetics:*Butyrophenone2622.61Benzamide1412.17Dexamethasone65.2Phenothiazine21.7Antihistamine32.61NK-143.5Anticholinergic00*Serotonin antagonists given with other antiemetic:*Serotonin antagonist + dexamethasone1311.3Serotonin antagonist + butyrophenone54.4Serotonin antagonist + benzamide00Serotonin antagonist + antihistamine10.9Serotonin antagonist + NK-110.9Serotonin antagonist + phenothiazine00*Placebo or no treatment*8674.78**Outcomes examined: frequency** ^d^Arrhythmia5346.1Delirium3429.6Mortality2824.3QT prolongation1815.7**Setting**Not reported7161.7Hospital2521.7Medical center1613.9Multi-center32.6^a^Includes unpublished data \[[@CR84]\]; ^b^duration is in hours unless otherwise noted; ^c^multiple interventions and comparators examined across the studies; ^d^multiple interventions and outcomes reported per study. NK-1: Neurokinin 1 receptor antagonist

The interventions examined were ondansetron (0.1−48 mg/day) (69 %), granisetron (0.1−3 mg/day) (12 %), tropisetron (0.3−5 mg/day) (13 %), dolasetron (12.5−200 mg/day) (13 %), palonosetron (0.025−0.07 mg/day) (4 %), and ramosetron (0.1−0.6 mg/day) (3 %). Some studies examined 5-HT~3~ receptor antagonists administered concomitantly with other antiemetics, dexamethasone (2--16 mg/day) (11 %) and droperidol (2.5 mg/day) (4 %), being the most common (Table [1](#Tab1){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Appendix 3).

Arrhythmia was the most frequently reported outcome (46 %). Only five studies reported QT prolongation, and 13 reported on the QT interval. None of the studies reported the number of patients experiencing PR prolongation or sudden cardiac death. We abstracted data from all of the included studies, and included 51 studies in our analyses. Reasons for excluding studies from the analyses included the manner in which the outcome was reported (e.g., mean versus number of patients), reporting zero events for all treatment arms, and investigating a single 5-HT~3~ receptor antagonist (with a different dosage in each treatment arm).

The average sample size was 242 participants ranging from 28 to 1,044, and 64% of participants were women (Table [2](#Tab2){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Appendix 4). Most of the studies involved only adult patients (63 %), patients with American Society of Anesthesiologists physical status I or II (58 %), and patients who were undergoing obstetrical and gynecological (32 %) surgery. Patients' history of postoperative nausea and vomiting was reported in 58% of the studies, and history of motion sickness was reported in 43 % of the studies. Comorbidities were rarely reported (6 %) (Table [2](#Tab2){ref-type="table"}).Table 2Patient characteristicsTotal number of patients27,787Mean sample size242Mean percentage female (%)64Number of studies (n = 115)^a^Percentage of studies (%)**Age category**Children only (aged \<18 years)2219.1Adults only (aged ≥18 years to ≤65 years)7262.6Children and adults (aged ≤65 years)21.7Adults and elderly (aged ≥18 years)1613.9All ages21.7Not reported10.9**American Society of Anesthesiologists (ASA) physical status**I43.5I or II6253.9I or II or III3227.8Not reported1714.8**Surgery type**Obstetric and gynecological3732.2Eye1210.4Gastrointestinal97.8General dentistry, oral and maxillofacial surgery, and orthodontics54.3Orthopedic54.3Neurological32.6Otolaryngological21.7Breast10.9Cardiovascular10.9Urological10.9Miscellaneous (includes multiple surgery types, abdominal surgery, and plastic surgery unspecified)3933.9**History of motion sickness**Yes4942.6No or not reported6657.4**History of postoperative nausea and vomiting**Yes6758.3No or not reported4841.7**Comorbidities** ^**b**^Not reported10994.8Diabetes mellitus32.6Cardiovascular21.7Obesity10.9Urological10.9Migraines10.9Liver disease10.9^a^Includes unpublished data; ^b^some studies considered more than one comorbidity

Methodological quality and risk of bias {#Sec12}
---------------------------------------

The majority of the included experimental and quasi-experimental studies had unclear or high risk of bias on the following items: allocation concealment (57 %), similarity of baseline outcome characteristics (88 %), incomplete outcome data (51 %), selective outcome reporting bias (97 %), and other types of bias, including the potential for funding bias because the study was funded by private industry and an author on the publication was employed by the company sponsoring the study (88 %) (Additional file [1](#MOESM1){ref-type="media"}: Appendix 5, 6). None of the 115 studies reporting harms outcomes fully reported all items on the McHarm tool (Additional file [1](#MOESM1){ref-type="media"}: Appendix 7, 8). The visual inspection of the comparison adjusted funnel plots showed that there was no evidence for small-study effects and publication bias (Additional file [1](#MOESM1){ref-type="media"}: Appendix 9).

Statistical analysis {#Sec13}
--------------------

### Arrhythmia {#Sec14}

The network meta-analysis for arrhythmia included 31 RCTs with 6,623 patients \[[@CR40], [@CR43], [@CR45], [@CR53], [@CR59], [@CR74], [@CR78], [@CR79], [@CR83], [@CR86]--[@CR89], [@CR97], [@CR102], [@CR108], [@CR112]--[@CR115], [@CR117], [@CR119], [@CR123], [@CR125], [@CR128], [@CR130], [@CR132], [@CR138], [@CR141], [@CR142], [@CR150]\]. The network geometry and included drugs can be found in Fig. [2a](#Fig2){ref-type="fig"}. Twenty-one studies were excluded from the analysis because they reported zero events in all arms \[[@CR39], [@CR43], [@CR57], [@CR60], [@CR61], [@CR71], [@CR73], [@CR81], [@CR82], [@CR86], [@CR90], [@CR92]--[@CR94], [@CR98], [@CR110], [@CR121], [@CR127], [@CR145], [@CR155], [@CR156]\]. Although the definitions of arrhythmia varied across the studies (Additional file [1](#MOESM1){ref-type="media"}: Appendix 10), there was no evidence of network inconsistency (*χ*^*2*^ = 3.49, degrees of freedom = 10, *P* = 0.968, heterogeneity variance = 0.01), and the within-network heterogeneity variance was estimated to be 0.00. Among patients of all ages receiving granisetron plus dexamethasone, significantly more experienced arrhythmia compared with placebo (OR 2.96, 95 % CI 1.11--7.94), ondansetron (OR 3.23, 95 % CI 1.17--8.95), dolasetron (OR 4.37, 95 % CI 1.51--12.62), tropisetron (OR 3.27, 95 % CI 1.02--10.43), and ondansetron plus dexamethasone (OR 5.75, 95 % CI 1.71--19.34) (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Appendix 11). According to the SUCRA curves (Additional file [1](#MOESM1){ref-type="media"}: Appendix 12), the safest agents for arrhythmia were ondansetron plus dexamethasone (83 % probability) and dolasetron (82 % probability).Fig. 2Network meta-analysis diagrams for (**a**) arrhythmia and (**b**) delirium. Nodes are proportional to the number of patients included in the corresponding treatments, and edges are weighted according to the number of studies included in the respective comparisons. Dex: Dexamethasone; Dolas: Dolasetron; Drop: Droperidol; Granis: Granisetron; Ondans: Ondansetron; Tropis: TropisetronFig. 3Network meta-analysis results for arrhythmia. All treatments are compared to placebo. The black horizontal lines represent the 95 % confidence intervals (CI) of the summary treatment effects and red horizontal lines the 95 % predictive intervals (PrI). Results are presented on the odds ratio (OR) scale. Among patients of all ages receiving granisetron plus dexamethasone, significantly more experienced arrhythmia compared with placebo (OR 2.96, 95 % CI 1.11--7.94), ondansetron (OR 3.23, 95 % CI 1.17--8.95), dolasetron (OR 4.37, 95 % CI 1.51--12.62), tropisetron (OR 3.27, 95 % CI 1.02--10.43), and ondansetron plus dexamethasone (OR 5.75, 95 % CI 1.71--19.34). Note: Reference treatment is placebo. CI: Confidence interval; OR: Odds ratio; PrI: Predictive intervalTable 3Statistically significant results of network meta-analysis for all time periods of drug administrationAll agesChildren onlyTreatment comparisonNumber of studiesMA estimate: OR (95 % CI)NMA estimate: OR (95 % CI)Number of studiesMA estimate: OR (95 % CI)NMA estimate: OR (95 % CI)Arrhythmia31 RCTs and 6,623 patients9 RCTs and 1,572 patientsGranisetron + DEX vs placebo22.63 (0.75-- 9.29)2.96 (1.11--7.94)14.89 (1.15--20.79)5.15 (1.33--19.91)Granisetron + DEX vs ondansetronNANA3.23 (1.17--8.95)NANA4.71 (1.08--20.46)Granisetron + DEX vs dolasetronNANA4.37 (1.51--12.62)NANANAGranisetron + DEX vs tropisetronNANA3.27 (1.02--10.43)NANANAGranisetron + DEX vs ondansetron + DEX28.10 (1.92--34.13)5.75 (1.71--19.34)17.67 (1.47--40.00)7.12 (1.66--30.63)CI: Confidence interval; DEX: Dexamethasone; MA: Meta-analysis; NA: Not applicable; NMA: Network meta-analysis; OR: Odds ratio

A subgroup analysis was conducted for 26 RCTs involving 4,878 patients in which the agents were administered during surgery \[[@CR40], [@CR43], [@CR45], [@CR53], [@CR59], [@CR74], [@CR78], [@CR79], [@CR83], [@CR86]--[@CR89], [@CR97], [@CR102], [@CR112], [@CR113], [@CR115], [@CR117], [@CR119], [@CR123], [@CR125], [@CR132], [@CR138], [@CR142], [@CR150]\]. The results were the same as for the primary analysis, except that significantly fewer patients of all ages receiving dolasetron experienced arrhythmia compared with placebo (OR 0.58, 95 % CI 0.36--0.93) and ramosetron (OR 0.38, 95 % CI 0.17--0.92) (Additional file [1](#MOESM1){ref-type="media"}: Appendix 13). According to the SUCRA curves for this subgroup analysis, the safest agents were dolasetron (86 % probability) and ondansetron plus dexamethasone (83 %).

Another subgroup analysis was conducted for nine RCTs involving a total of 1,572 patients to examine the intra-operative administration of ondansetron, ondansetron plus dexamethasone, and granisetron plus dexamethasone to children (Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Appendix 13) \[[@CR53], [@CR79], [@CR86], [@CR89], [@CR97], [@CR113], [@CR117], [@CR123], [@CR138]\]. Significantly more children receiving granisetron plus dexamethasone during surgery experienced arrhythmia compared with placebo (OR 5.15, 95 % CI 1.33--19.91), ondansetron (OR 4.71, 95 % CI 1.08--20.46), and ondansetron plus dexamethasone (OR 7.12, 95 % CI 1.66--30.63). According to the SUCRA curves, the safest agent in terms of arrhythmia was ondansetron plus dexamethasone (80 % probability). Finally, a sensitivity analysis was conducted in which one RCT was removed because of high risk of incomplete outcome data \[[@CR128]\], and the same results were observed (Additional file [1](#MOESM1){ref-type="media"}: Appendix 13).

### Delirium {#Sec15}

The network meta-analysis for delirium included 18 studies involving 3,652 patients in which ondansetron, granisetron, dolasetron, tropisetron, and dolasetron plus dexamethasone were administered during surgery \[[@CR52], [@CR60], [@CR68], [@CR69], [@CR76], [@CR79], [@CR96], [@CR100], [@CR105], [@CR106], [@CR118], [@CR124], [@CR128], [@CR133], [@CR137], [@CR139], [@CR144], [@CR146]\]. The network geometry and included drugs can be found in Fig. [2b](#Fig2){ref-type="fig"}. Ten studies were excluded from the analysis because they reported zero events in all arms \[[@CR49], [@CR69], [@CR75], [@CR90], [@CR99], [@CR103], [@CR129], [@CR135], [@CR140], [@CR143]\]. No statistically significant results were observed and the within-network heterogeneity variance in the network meta-analysis model was estimated to be 0.00 (Additional file [1](#MOESM1){ref-type="media"}: Appendix 14). Although the definitions of delirium varied across the studies (Additional file [1](#MOESM1){ref-type="media"}: Appendix 15, 16), there was no evidence of network inconsistency (*χ*^*2*^ = 0.32, degrees of freedom = 2, *P* = 0.851, heterogeneity variance = 0.00).

### Mortality {#Sec16}

A meta-analysis was conducted for three studies including 1,255 patients that reported mortality for comparisons of ondansetron with placebo \[[@CR10], [@CR111], [@CR142]\]. No statistically significant effects were observed (OR 1.92, 95 % CI 0.30--12.21). Twenty-five studies were excluded from this analysis because they reported zero events in both arms \[[@CR38], [@CR41], [@CR44], [@CR55], [@CR56], [@CR58], [@CR62], [@CR67], [@CR70], [@CR72], [@CR77], [@CR78], [@CR80], [@CR107], [@CR109], [@CR115], [@CR120], [@CR126], [@CR128], [@CR130], [@CR131], [@CR134], [@CR149], [@CR157], [@CR158]\].

### QT prolongation {#Sec17}

Two RCTs reported the number of patients experiencing QT prolongation \[[@CR55], [@CR116]\]. In one of these studies, there was no statistically significant difference between ondansetron and placebo (OR 0.75, 95 % CI 0.47--1.20) \[[@CR55]\], and in the other there was no statistically significant difference between granisetron and placebo (OR 0.32, 95 % CI 0.01--8.02) \[[@CR116]\]. Three studies did not inform the analysis and were excluded, as they reported zero events in both arms \[[@CR58], [@CR115], [@CR159]\].

Discussion {#Sec18}
==========

More patients receiving granisetron plus dexamethasone experienced arrhythmia compared to other agents. The safest 5-HT~3~ receptor antagonists with respect to arrhythmia were ondansetron plus dexamethasone and dolasetron for patients of all ages and ondansetron plus dexamethasone for children (none of the included studies examined dolasetron in children). These results were consistent across subgroup and sensitivity analyses. None of the agents caused significantly more patients to experience delirium. Few studies reported QT prolongation, and no statistically significant results for this outcome were reported in the two studies reporting at least one event. As well, no statistically significant differences in mortality were observed between ondansetron and placebo in a meta-analysis of three studies that reported this outcome. None of the studies included in this analysis reported the number of patients experiencing PR prolongation or sudden cardiac death.

Our finding of no increased risk of cardiac arrhythmia in association with ondansetron therapy supports the results of a previous systematic review \[[@CR160]\]. Although we are aware of other systematic reviews and meta-analyses of 5-HT~3~ receptor antagonists \[[@CR9], [@CR161]\], the previous researchers did not conduct network meta-analysis, so we cannot compare our results with theirs. Notably, because of our comprehensive literature search and broad eligibility criteria, we included 62 studies involving a total of 14,705 patients that were not included in any of the previous reviews (Additional file [1](#MOESM1){ref-type="media"}: Appendix 17).

We found no increased risk of arrhythmia with dolasetron for patients of any age. This does not mean that a cardiac risk does not exist; we found no studies examining other cardiac harms, such as PR prolongation and sudden cardiac death. We identified no studies examining dolasetron administered to children. We found other data gaps through the conduct of this review. In particular, most of the studies focused on effectiveness outcomes, and relatively few reported harms. Our network meta-analysis results for the effectiveness outcomes have been reported in another publication \[[@CR8]\].

The studies included in our analysis had some methodological limitations. Most of the studies were small (average sample size 242 patients) and larger sample sizes are required to assess harms, in particular harms that occur only rarely, such as arrhythmia and delirium. Indeed, the need for larger sample sizes is the reason we included non-randomized studies in our review. Although these non-randomized studies involved more patients than the RCTs, their inclusion did not change the network meta-analysis results obtained for arrhythmia or delirium. As well, many of the studies failed to report baseline characteristics or all items assessed by the McHarm tool, and many of the included trials had an unclear or high risk of bias on important items for the conduct of trials, including allocation concealment, selective outcome reporting bias, and potential for funding bias.

Our systematic review process also had some limitations. Slight changes to our original protocol \[[@CR7]\] were necessary, because of the enormous number of studies that met our inclusion criteria. For example, we were unable to report data on patients undergoing chemotherapy in this paper (but these will be disseminated in an upcoming paper), we did not include studies written in languages other than English, and we focused inclusion to unpublished conference abstracts from the past 10 years that included relevant data. However, we were able to include unpublished data from one study \[[@CR84]\], and our funnel plots showed no evidence of small-study effects or publication bias. Furthermore, we assumed that the effects of the different doses and durations were identical across the treatments, and that they defined the same node they belong to. We are currently exploring these assumptions in another paper \[[@CR162]\]. Finally, we had to exclude 77 studies because they contained data known or suspected to be fraudulent, as identified by editors and authors in the field and presented in a paper \[[@CR9]\]; we did not conduct a sensitivity analysis including these articles to examine the effect of excluding these studies on our results.

Conclusion {#Sec19}
==========

We conclude that most 5-HT~3~ receptor antagonists that do not cause delirium. Granisetron plus dexamethasone increased the risk of cardiac harm (arrhythmia), with the number needed to harm ranging from five to eight. We are unable to comment on the relationship between 5-HT~3~ receptor antagonists and other cardiac harms, such as for PR prolongation and sudden cardiac death, as no studies reported these important outcomes.

Additional file {#Sec20}
===============

Additional file 1:**Appendix 1--17. Includes 17 appendices with supplementary data.**
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